AGLE - Aeglea BioTherapeutics, Inc.
| Previous Close | 7.88 |
| Open | 7.99 |
| Bid | 6.80 x 1000 |
| Ask | 7.98 x 300 |
| Day's Range | 7.72 - 7.99 |
| 52 Week Range | 2.81 - 11.35 |
| Volume | 292,016 |
| Avg. Volume | 119,942 |
| Market Cap | 131.557M |
| Beta | -0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.80 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.50 |
- GlobeNewswire•3 days ago
Aeglea BioTherapeutics Prices Public Offering of Common Stock
AUSTIN, Texas, April 18, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•5 days ago
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, April 17, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•10 days ago
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities. Clinically Relevant Improvement Seen in Multiple Neuromotor Tests. Company to Host Clinical Update Conference Call Today ...
- GlobeNewswire•17 days ago
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
AUSTIN, Texas, April 05, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Zacks•19 days ago
Aeglea Initiates Lung Cancer Combination Study With Keytruda
Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.
- GlobeNewswire•19 days ago
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
AUSTIN, Texas, April 03, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•20 days ago
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
AUSTIN, Texas, April 02, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of AGLE earnings conference call or presentation 13-Mar-18 12:00pm GMT
Q4 2017 Aeglea Bio Therapeutics Inc Earnings Call
- GlobeNewswire•27 days ago
Aeglea BioTherapeutics Appoints Dr. Ivana Magovčević-Liebisch to Board of Directors
AUSTIN, Texas, March 26, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•last month
Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
AUSTIN, Texas, March 20, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Simply Wall St.•last month
Want To Invest In Aeglea Biotherapeutics Inc (NASDAQ:AGLE)? Here’s How It Performed Lately
When Aeglea Biotherapeutics Inc (NASDAQ:AGLE) announced its most recent earnings (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...
- GlobeNewswire•last month
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
Repeat Doses of Company’ s Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels. Accompanying Reductions in Other Related Guanidino Compounds Also Seen. Additional Arginase ...
- GlobeNewswire•last month
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
AUSTIN, Texas, March 08, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders
AUSTIN, Texas, March 06, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Capital Cube•4 months ago
ETFs with exposure to Aeglea Biotherapeutics, Inc. : December 28, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aeglea Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to AGLE-US. Comparing the performance and risk of Aeglea Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•4 months agoAeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
Categories: Yahoo FinanceGet free summary analysis Aeglea Biotherapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aeglea Biotherapeutics, Inc. – Onconova Therapeutics Inc., Ono Pharmaceutical Co., Ltd. Unsponsored ADR and Omeros Corporation (ONTX-US, OPHLY-US and OMER-US) that have also reported for this period. Highlights ... Read more (Read more...)
- Simply Wall St.•4 months ago
Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?
Aeglea Biotherapeutics Inc (NASDAQ:AGLE), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is AGLERead More...
- Capital Cube•5 months ago
ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 29, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aeglea Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to AGLE-US. Comparing the performance and risk of Aeglea Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
